Zytiga Patent Expiration

Zytiga is a drug owned by Janssen Biotech Inc. It is protected by 2 US drug patents filed from 2013 to 2017. Out of these, 1 drug patents are active and 1 has expired. Zytiga's patents have been open to challenges since 29 April, 2015. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 24, 2027. Details of Zytiga's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822438 Methods and compositions for treating cancer
Aug, 2027

(2 years from now)

Active
US5604213 17-substituted steroids useful in cancer treatment
Feb, 2014

(10 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zytiga's patents.

Given below is the list of recent legal activities going on the following patents of Zytiga.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 16 Feb, 2022 US8822438
Review Certificate Mailed 21 Oct, 2019 US8822438
Review Certificate 11 Sep, 2019 US8822438
Payment of Maintenance Fee, 4th Year, Large Entity 15 Feb, 2018 US8822438
Post Issue Communication - Certificate of Correction 02 Feb, 2018 US8822438
Termination or Final Written Decision 17 Jan, 2018 US8822438
Post Issue Communication - Certificate of Correction 12 Dec, 2017 US8822438
Post Issue Communication - Certificate of Correction 06 Oct, 2017 US8822438
Workflow - Request for CPA - Begin 08 Aug, 2017 US8822438
Request for Trial Granted 12 Apr, 2017 US8822438


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Zytiga and ongoing litigations to help you estimate the early arrival of Zytiga generic.

Zytiga's Litigations

Zytiga been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 08, 2017, against patent number US8822438. The petitioner ACTAVIS LABORATORIES FL, INC., challenged the validity of this patent, with Janssen Oncology, Inc. as the respondent. Click below to track the latest information on how companies are challenging Zytiga's patents.

Last updated on December 3, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8822438 December, 2015 FWD Entered
(17 Jan, 2018)
Janssen Oncology, Inc. Amerigen Pharmaceuticals, Ltd.
US8822438 June, 2016 FWD Entered
(17 Jan, 2018)
Janssen Oncology, Inc. Argentum Pharmaceuticals LLC
US8822438 June, 2016 FWD Entered
(17 Jan, 2018)
Janssen Oncology, Inc. Mylan Pharmaceuticals Inc.
US8822438 August, 2016 FWD Entered
(17 Jan, 2018)
Janssen Oncology, Inc. Wockhardt Bio AG
US8822438 February, 2017 FWD Entered
(17 Jan, 2018)
Janssen Oncology, Inc. ACTAVIS LABORATORIES FL, INC.


FDA has granted some exclusivities to Zytiga. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Zytiga, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Zytiga.

Exclusivity Information

Zytiga holds 3 exclusivities. All of its exclusivities have expired in 2021. Details of Zytiga's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-663) Dec 10, 2015
New Chemical Entity Exclusivity(NCE) Apr 28, 2016
New Indication(I-765) Feb 07, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Zytiga is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zytiga's family patents as well as insights into ongoing legal events on those patents.

Zytiga's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Zytiga's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 24, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Zytiga Generic API suppliers:

Abiraterone Acetate is the generic name for the brand Zytiga. 13 different companies have already filed for the generic of Zytiga, with Teva Pharms Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zytiga's generic

How can I launch a generic of Zytiga before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Zytiga's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Zytiga's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Zytiga -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
250 mg 28 Apr, 2015 13 31 Oct, 2018 24 Aug, 2027 Eligible
500 mg 23 Aug, 2017 1 24 Aug, 2027 Extinguished

Alternative Brands for Zytiga

Zytiga which is used for the treatment of advanced prostate cancer in combination with prednisone, including metastatic castration-resistant and high-risk castration-sensitive types., has several other brand drugs using the same active ingredient (Abiraterone Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Janssen Biotech
Akeega
Sun Pharm
Yonsa


Apart from brand drugs containing the same ingredient, some generics have also been filed for Abiraterone Acetate, Zytiga's active ingredient. Check the complete list of approved generic manufacturers for Zytiga





About Zytiga

Zytiga is a drug owned by Janssen Biotech Inc. It is used for the treatment of advanced prostate cancer in combination with prednisone, including metastatic castration-resistant and high-risk castration-sensitive types. Zytiga uses Abiraterone Acetate as an active ingredient. Zytiga was launched by Janssen Biotech in 2011.

Approval Date:

Zytiga was approved by FDA for market use on 28 April, 2011.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Zytiga is 28 April, 2011, its NCE-1 date is estimated to be 29 April, 2015.

Active Ingredient:

Zytiga uses Abiraterone Acetate as the active ingredient. Check out other Drugs and Companies using Abiraterone Acetate ingredient

Treatment:

Zytiga is used for the treatment of advanced prostate cancer in combination with prednisone, including metastatic castration-resistant and high-risk castration-sensitive types.

Dosage:

Zytiga is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
250MG TABLET Prescription ORAL
500MG TABLET Prescription ORAL


Zytiga News

J&J cautions about potential impact from generic drugs in third quarter, leading to decline in shares.

07 Jul, 2024

Court in United States invalidates patent for Johnson & Johnson's cancer drug Zytiga, announces Yahoo News

04 Jul, 2024

Johnson & Johnson cautions about impact of generic drugs in third quarter, leading to decline in shares - Report by Yahoo News Singapore

05 May, 2024

See More